Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZVS203e in Retinitis Pigmentosa Caused by RHO Mutations
NCT05805007Phase 1Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ZVS203e in retinitis pigmentosa (RP), sponsored by Peking University Third Hospital. Primary endpoints: Adverse Events and Serious Adverse Events at 52 weeks, Immunogenicity Testing at 52 weeks and 1 more. Started Sep 2023; status: recruiting.
02
Drugs
ZVS203e
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT05805007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805007.